Tata Proteomics and Coagulation Unit, Thrombosis Research Institute, Bangalore 560099, India.
Manipal University, Madhav Nagar, Manipal 576104, Karnataka, India.
Int J Mol Med. 2017 Aug;40(2):531-538. doi: 10.3892/ijmm.2017.3031. Epub 2017 Jun 19.
Conventional risk factors have limited ability to predict recurrent events in subjects with first-time coronary artery disease (CAD). This aim of this study was to identify novel biomarkers using comparative global proteome analysis to improve the risk assessment for recurrent coronary events. We used samples from phase-I of the Indian Atherosclerosis Research Study (IARS), consisting of 2,332 subjects, of whom 772 were CAD-affected subjects, including 152 with recurrent events identified during a 5-year follow-up period. Global proteome analysis was performed on serum samples of 85 subjects with recurrent coronary events and 85 age- and gender-matched subjects with first-time CAD using surface-enhanced laser desorption ionization time-of-flight mass spectrometry with CM10 arrays. TagIdent was used for protein identification followed by validation by western blot analysis and ELISA. Data were analyzed by logistic analysis, Cox-regression, hazards ratio, C-statistics and combined-marker risk score using SPSS version-17 and R-package version-2.13.0 software. We identified 16 significantly differentially expressed protein peaks. Of these, 2 peaks corresponding to m/z 8588 and 1864 were identified as β-defensin-128 and histatin-3, belonging to the danger-recognizing peptide family, which exhibited a significant independent association with recurrent events (odds ratios of 7.49 and 1.4, respectively). C-statistics improved significantly from 0.677 for conventional risk factors alone to 0.800 (p-value=0.001) in combination with β-defensin-128 and histatin-3 with a hazards ratio of 1.833. A combined risk score of β-defensin-128 and histatin-3 could reclassify 112 out of the 170 subjects into intermediate- and high-risk groups. On the whole, our data indicate that β-defensin-128 and histatin-3 may be potential biomarkers whch may be used to improve risk the stratification for recurrent coronary events.
传统的危险因素对首次发生冠状动脉疾病 (CAD) 的患者的复发性事件的预测能力有限。本研究的目的是使用比较全蛋白质组分析来识别新型生物标志物,以改善复发性冠状动脉事件的风险评估。我们使用印度动脉粥样硬化研究(IARS)I 期的样本,该研究包含 2332 名受试者,其中 772 名是 CAD 患者,包括 152 名在 5 年随访期间发生复发性事件的患者。使用表面增强激光解吸电离飞行时间质谱与 CM10 阵列对 85 名复发性冠状动脉事件患者和 85 名年龄和性别匹配的首次发生 CAD 的患者的血清样本进行全蛋白质组分析。使用 TagIdent 进行蛋白质鉴定,然后通过 Western blot 分析和 ELISA 进行验证。使用 SPSS 版本 17 和 R 包版本 2.13.0 软件通过逻辑分析、Cox 回归、危险比、C 统计量和联合标志物风险评分分析数据。我们鉴定出 16 个差异表达显著的蛋白峰。其中,2 个对应于 m/z 8588 和 1864 的峰被鉴定为β-防御素-128 和组织胺-3,属于危险识别肽家族,与复发性事件显著独立相关(比值比分别为 7.49 和 1.4)。与β-防御素-128 和组织胺-3 联合使用时,C 统计量从单独使用传统危险因素的 0.677 显著提高到 0.800(p 值=0.001),危险比为 1.833。β-防御素-128 和组织胺-3 的联合风险评分可将 170 名患者中的 112 名重新分类为中危和高危组。总的来说,我们的数据表明,β-防御素-128 和组织胺-3 可能是潜在的生物标志物,可用于改善复发性冠状动脉事件的风险分层。